▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #441 by analyst upside · 2026-11-13
CCCC
C4 Therapeutics, Inc.
Healthcare · Market Cap $364M · P/E 0x
ANALYST PRICE TARGET
+351.3%
implied upside to consensus target
Current Price $2.77
Consensus Target $12.5
Bull Target $30.0
Bear Target $6.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
0
Sell
0
52-Week Low $1.69
52-Week High $5.17
YTD Return +43.5%
FUNDAMENTALS
Market Cap $364M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.63
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $32M
Profit Margin -282.2%
52-WEEK RANGE
52-Week Low $1.69
52-Week High $5.17
Current Price $2.77
Bear Target $6.0
Bull Target $30.0
● Now $2.77 ● Target $12.5
TRADING DATA
Avg Volume 2.5M
YTD Return +43.5%
Analyst Count 8
Consensus Buy
Upside to Target +351.3%
Last Updated 2026-11-13

ANALYST SUMMARY

C4 Therapeutics, Inc. (CCCC) is currently trading at $2.77 with a Wall Street consensus price target of $12.5, implying potential upside of 351.3% over the next 12 months. 8 analysts currently cover CCCC, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $6.0.

CCCC operates in the Healthcare sector with a market capitalisation of $364M. The stock is up 43.5% year-to-date and is currently trading near the lower end of its 52-week range of $1.69 – $5.17.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CCCC, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim - Reiterated
Buy → Buy 2026-11-06 62% win rate (8 calls)
Lake Street ● Initiated
Buy 2026-10-28 27% win rate (11 calls)
JP Morgan ● Initiated
Overweight 2026-10-09 43% win rate (7 calls)
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-06-01 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-02-27 Building track record
Brookline Capital - Reiterated
Buy → Buy 2026-02-23 20% win rate (5 calls)
Barclays - Reiterated
Overweight → Overweight 2025-12-17 Building track record
TD Cowen ● Initiated
Buy 2025-12-02 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →